ARD-101 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
ARD-101 made adults less hungry by switching on bitter taste receptors in the gut. Both of its final-stage studies, in a rare hunger disorder called Prader-Willi syndrome, were stopped.
Evidence grade for ARD-101: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, 20 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 20
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 20 people given it
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
ARD-101 is an experimental pill that switches on bitter taste receptors in your gut. That makes your gut release its own fullness hormones. It was aimed at Prader-Willi syndrome, a rare disorder of hunger that never stops. Both final-stage studies were stopped. It is not approved.
What people take it for
- Less hunger.
- Weight loss.
- Hunger control in Prader-Willi syndrome.
What studies in people showed
The final-stage study in Prader-Willi syndrome had 68 people and was stopped. Its follow-on study had 19 and was stopped too. No results have been posted, and no reason given. Before that, in a small study, adults with obesity took it for 28 days. They felt less hungry, had fewer food cravings, and lost 0.8 kg more than people on a dummy pill. In obese mice, weight loss was bigger, but only with a second drug added.
What people report
Reports, not study results
The good
- In the small study, people reported less hunger and fewer food cravings.
The bad
- Weight loss in people was small, 0.8 kg more than the dummy pill at day 28.
- Both final-stage studies were stopped.
Where these come from: The hunger and weight results are from the study and registry records on this page. There are no forum reports, since the drug was never sold.
My bottom line
Clever idea, and I hope someone keeps at it. But feeling less hungry is not losing weight, and the main studies stopped. Right now this is a maybe, not a treatment.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals ARD-101 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 1 study
- Feeling less hungryno headcount stated · 1 study
34 of the 36 indexed goals have no study of any kind behind ARD-101
No study in people, animals or cells on this page reports a result for these. That does not prove ARD-101 does nothing for them. It does mean anything you have heard about ARD-101 and one of these did not come from a study cited here.
Show full evidence
What is ARD-101?
ARD-101 made adults less hungry by switching on bitter taste receptors in the gut. Both of its final-stage studies, in a rare hunger disorder called Prader-Willi syndrome, were stopped.
Bitter taste receptors are not just on your tongue. They line your gut too. Switching them on there makes the gut release hormones that make you feel full, including GLP-1. ARD-101 was built to use that. It is meant to stay in the gut, switch on those receptors, and get the body to release its own fullness hormones. It does not copy a hormone itself.
That is a clever idea. It is the same thinking behind linaclotide: if your target is on the gut lining, the drug does not need to get into the blood.
It made it to studies in people. In a small study, 20 adults with obesity took it or a dummy pill for 28 days. They felt less hungry and had fewer food cravings, and lost a little more weight, 0.8 kg more by day 28. Its main target was Prader-Willi syndrome, a genetic disorder where the key feature is hunger that never stops, and where no good treatment exists.
Both final-stage studies in that disorder are marked as stopped on the study registry.
How does ARD-101 work?
ARD-101 is a pill that switches on bitter taste receptors. It is built to stay inside the gut and not get absorbed into the blood. Special cells all along the gut carry these receptors. When they are switched on, those cells release the body's own fullness hormones, including GLP-1 and a few others. So the drug prompts the body to release its own hormones, instead of standing in for them. In theory, that keeps the body's natural on-and-off rhythm. A drug that copies a hormone around the clock overrides that rhythm.
What have studies in people found about ARD-101?
One published study showing less hunger in people, and one small finished study, against two stopped final-stage studies in the main target disorder.
- The final-stage study in Prader-Willi syndrome enrolled 68 people. It was stopped.
- 20 adults with obesity took it or a dummy pill for 28 days. They felt less hungry, which is the drug working as designed. That study was finished.
- The follow-on study, where everyone knew they were getting the drug, enrolled 19. It was also stopped.
- The bigger weight loss result in the same paper is in obese mice, and only when a second drug was added.
- Not approved anywhere, and no final-stage result has been published.
What this does not tell you: Feeling less hungry and losing weight are different things. In people, this drug has only shown the first. The bigger weight loss was only in mice, with a second drug added. The studies in people are small, 20 people in the finished one. Two stopped final-stage studies in the main target disorder is a serious fact. The registry does not say why, so this page does not guess. Prader-Willi syndrome is also a very hard disorder to treat. Failing there does not fully settle whether the idea works for ordinary obesity.
The state of the research
ARD-101 is worth recording because the idea deserves to be remembered, even though the program stopped.
Most weight-loss drugs supply a hormone or copy one. That overrides the body's own control, and it brings the side effects of a hormone signal that never switches off. This drug tried something different. Stay in the gut, switch on receptors that are already there, and let the body release its own fullness hormones on its own schedule. If that worked, it would keep the body's natural rhythm in a way a shot cannot.
The results in people say the idea does something. Adults felt less hungry. What it has not shown is that less hunger means real weight loss in people. The bigger weight loss was in mice, and it needed a second drug.
And the most advanced studies, in a disorder defined by hunger that never stops, where nothing works well, were stopped. Whether that was the drug, the disorder or a business decision is not public, and this page does not guess.
The evidence, in charts
Fig. 1a · how many people
20people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| ClinicalTrials.gov 2024 | 20 | 100% |
The whole total is one study of 20. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 3 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 4 sources here are studies in people.
- Study in people · done in people4100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2024 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- A small molecule. No mass asserted; no source loaded states one.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not meaningfully described systemically, since the molecule is designed to remain gut-restricted with minimal absorption.
No amino acid sequence is on file for ARD-101, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2026ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition
ARD-101 made people less hungry. The headline weight loss belongs to mice. Adults with obesity took 200 mg twice a day for 28 days, or a dummy pill. They lost 0.8 kg more than the dummy group by day 28, and 1.3 kg by the end. They also reported less hunger and fewer food cravings. The bigger weight loss in the paper came from obese mice, and only when a second drug was added. The drug's maker employs most of the authors.
Reports reduced hunger in adults from a gut-restricted bitter taste receptor agonist, alongside weight loss in diet-induced obese mice when combined with a DPP-4 inhibitor. Note the split: the human result is on hunger, and the weight loss result is in mice and required a second drug.
- Study in people2024A study to evaluate ARD-101 in adults with obesity
This is the sign-up record for the small obesity study, not a separate result. It was an early study in 20 people, and it is marked finished. That is the size most of the proof in people for this drug is. The published paper has the result. This record only adds the size and the status.
Phase 2, 20 participants, completed. A small early study, which is the scale most of the human data here comes from.
- Study in people2026ARD-101 for treatment of Prader-Willi syndrome: the Hunger Elimination or Reduction Objective trial
The study this whole program was built around was stopped. It was the final-stage study in Prader-Willi syndrome, the disorder ARD-101 was aimed at, and 68 people had signed up. The registry gives no result. A stopped main study is not a small thing. It is the point where the program in its main target ended.
Phase 3, 68 participants, status TERMINATED. The pivotal trial in the indication the programme was built around.
- Study in people2026The Hunger Elimination or Reduction Objective open-label extension trial
The follow-on study was stopped too, so both halves of the program ended. 19 people had signed up, and everyone knew they were getting the drug. No results have been posted. When the main study and its follow-on both stop, the honest reading is that the program for this disorder is over, not paused.
The open-label extension, 19 participants, status TERMINATED. Both arms of the phase 3 programme ended.
Common questions
Has ARD-101 been tested in people?
Yes. 20 people given it across 1 completed trial cited here, 0 of which found nothing. ARD-101 made adults less hungry by switching on bitter taste receptors in the gut. Both of its final-stage studies, in a rare hunger disorder called Prader-Willi syndrome, were stopped.
What is the ARD-101 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 20 people given it
Is ARD-101 FDA-approved?
Never approved. Both final-stage studies in Prader-Willi syndrome, a rare genetic condition, are listed as TERMINATED (stopped) on ClinicalTrials.gov.
How can a bitter taste receptor make you less hungry?
Because those receptors are not only on your tongue. They line your gut. Switching them on there makes special gut cells release your body's own fullness hormones, including GLP-1. The drug prompts your own hormones instead of standing in for them.
Did it cause weight loss?
In people, it made them less hungry. In a small 28-day study, they lost 0.8 kg more than people on a dummy pill. The bigger weight loss in the same paper was in obese mice, and needed a second drug added. Feeling less hungry and losing weight are different things. Only the first has been clearly shown in people.
Why did the phase 3 trials stop?
The registry lists both the main Prader-Willi study and its follow-on study as stopped, and gives no reason. So this site does not give one either. It is worth knowing that Prader-Willi syndrome is a very hard disorder to treat. Failing there does not by itself settle whether the idea works for ordinary obesity.